Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

NIH Seeks Modular Trailer for Manufacturing Critical Retroviral Vectors

by Global Biodefense Staff
July 20, 2016
NIH Clinical Center Pharmaceutical Development Section

The NIH Clinical Center in Bethesda, Md. Credit: NIH

NIH Clinical Center Pharmaceutical Development Section
The NIH Clinical Center in Bethesda, Md. Credit: NIH

The recent shutdown of the National Institutes of Health (NIH) Clinical Center Pharmaceutical Development Section (PDS) due to problems with quality control has prompted NIH to seek an interim solution to continue manufacturing novel retroviral vectors to support ongoing gene-therapy trials.

In a solicitation issued this week, NIH is seeking a mobile clean room ‘Viral Vector Trailer’ that would allow them to continue manufacture of cGMP viral vectors previously handled its Surgery Branch Vector Production Facility.

The Surgery Branch was responsible for the development of interleukin-2 (IL-2), the first effective immunotherapy in humans, the development of cell transfer immunotherapies for melanoma and other solid cancers, the first insertion of foreign genes into humans and the first development of effective human cancer immunotherapies based on the genetic engineering of autologous lymphocytes with genes encoding anti-tumor T cell receptors or chimeric antigen receptors.

The Surgery Branch Vector Production Facility develops and manufactures cGMP quality master cell banks and viral vectors encoding T cell receptors or chimeric antigen receptors for the ex vivo genetic modification of T lymphocytes.  Patient therapies are administered based on our ability to genetically re-direct autologous T lymphocytes using retroviral vectors to specifically target solid cancers and certain hematologic malignancies.

“Since our prior vector production facility was closed in March 2016, we have no facility to produce these vectors,” states the announcement. “The program urgently requires an interim space meeting the cGMP requirements to continue preparation of these essential patient treatment products.”

While several gene therapy programs are being developed in the Surgery Branch, they are currently focused on two major initiatives:

  • Development and manufacture of multiple retroviral vectors encoding TCRs targeting a shared hot-spot mutation in KRAS primarily for the treatment of patients with lung and pancreatic cancers.
  • The identification TCRs targeting unique somatic mutations expressed by a patient’s tumor and the subsequent genetic modification of autologous T lymphocytes with these unique TCRs using retroviral vectors for a personalized immunotherapy.

These programs have pre-clinical data to support that the treatment concept is sound and clinical protocols that have been through the CCR review process, but cannot be moved into the Investigational New Drug (IND) Applications phase due to lack of production facilities.

In addition to meeting the needs of cGMP viral vector manufacturing, the envisioned modular facility would also serve as a temporary backup (if necessary) for NIH’s Intravenous Admixture Unit (IVAU), which produces pain and other pharmaceuticals for the current patient population. The IVAU’s current lack of a suitable backup manufacturing facility has been identified as a critical risk – one that NIH hopes to mitigate by rolling requirements for IVAU production into the proposed modular facility.

Further details are available via Solicitation Number: NIHOF2016128. The request for quotation closes on July 29, 2016.

Tags: NIHRequest for Quotes

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC